ONE-WAYDated event · through FY2021-Q2
Discontinuation of KRP-203 development, return of rights and transfer to Priothera
A standalone event in which, following Novartis’ discontinuation of development of KRP-203, development rights and other rights were returned, after which intellectual property, active pharmaceutical ingredients and other assets were transferred to Priothera.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2018-Q3 →Last written FY2021-Q2
Directionhurts0 helps · 1 hurts · 0 flat